Pitolisant hydrochloride

Pitolisant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated in hypersomnia and narcolepsy-cataplexy syndrome. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Wakix (TN) and Ciproxidine. Its PubChem CID is 11551689.

CAS No 903576-44-3
Molecular Formula C17H27Cl2NO
Molecular Weight 332.3 g/mol
Synonyms 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride

Frequently Asked Questions